Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 3/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.51 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.51 |
| ▸ | AKT1 | P31749 | 2/20 | 0.49 |
| ▸ | AKT2 | P31751 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3345764 | 0.83 | RAB9A (0.51) | ADRB2ADRB1ADRB3AKT2LMNA | |
| SCHEMBL16293426 | 0.83 | ADRB2 (0.51) | ADRB2ADRB1ADRB3LMNAHPGD | |
| SCHEMBL6836530 | 0.81 | MEN1 (0.62) | LMNAMAPTMEN1KMT2AKDM4E | |
| SCHEMBL27978807 | 0.81 | ADRB2 (0.49) | ADRB2ADRB1ADRB3MAPK1MAPT | |
| SCHEMBL14938246 | 0.80 | DRD2 (0.54) | ADRB2ADRB1ADRB3LMNASMN1; SMN2 | |
| SCHEMBL13597059 | 0.80 | ADRB2 (0.48) | ADRB2ADRB1ADRB3MAPK1MAPT | |
| SCHEMBL27978531 | 0.80 | ADRB2 (0.58) | ADRB2ADRB1ADRB3AKT1LMNA | |
| SCHEMBL3341397 | 0.79 | MAPT (0.54) | ADRB2ADRB1ADRB3MAPK1MAPT | |
| SCHEMBL14964955 | 0.78 | POLB (0.49) | ADRB2ADRB1ADRB3POLBKMT2A | |
| SCHEMBL4432115 | 0.78 | LMNA (0.72) | LMNAHPGDSMN1; SMN2POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140371203-A1 | Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors | XENTION LIMITED (GB) | 2014-12-18 | — | — | US | claimed |
| CN-104011054-A | Thieno- and furo-pyrimidines and pyridines, useful as potassium channel inhibitors | XENTION LTD | 2014-08-27 | — | — | CN | claimed |
| US-20160152634-A1 | THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS | XENTION LTD (GB) | 2016-06-02 | — | — | US | disclosed |
| US-9290511-B2 | Thieno-pyrimidines, useful as potassium channel inhibitors | XENTION LIMITED (GB) | 2016-03-22 | — | — | US | disclosed |
| US-20140371203-A1 | Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors | XENTION LIMITED (GB) | 2014-12-18 | — | — | US | disclosed |
| CN-104011054-A | Thieno- and furo-pyrimidines and pyridines, useful as potassium channel inhibitors | XENTION LTD | 2014-08-27 | — | — | CN | disclosed |
| US-8207174-B2 | Beta-3 adrenergic receptor agonists; urinary tract infections, incontinence, gastrointestinal disorders, dysmenorrhea, obesity; tocolytic, anxiolytic, antidiabetic agents; antidepressants; 4-(2-hydroxy-3-(1-(5-phenylthieno[2,3-d]pyrimidin-4-yl)piperidin-4-ylamino)propoxy)phenol | 4SC AG (DE) | 2012-06-26 | — | — | US | disclosed |
| EP-2118086-A1 | ARYLOXYPROPANOLAMINES, METHODS OF PREPARATION THEREOF AND USE OF ARYLOXYPROPANOLAMINES AS MEDICAMENTS | 4SC AG (DE) | 2009-11-18 | — | — | EP | disclosed |
| US-20080249114-A1 | ARYLOXYPROPANOLAMINES, METHODS OF PREPARATION THEROF AND USE OF ARYLOXYPROPANOLAMINES AS MEDICAMENTS | SCHWARZ PHARMA AG (DE) | 2008-10-09 | — | — | US | disclosed |
| WO-2008090140-A1 | ARYLOXYPROPANOLAMINES, METHODS OF PREPARATION THEREOF AND USE OF ARYLOXYPROPANOLAMINES AS MEDICAMENTS | 4SC AG (DE) | 2008-07-31 | — | — | WO | disclosed |
| EP-1947103-A1 | Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments | 4SC AG (DE) | 2008-07-23 | — | — | EP | disclosed |
| US-20040138238-A1 | Substituted aminopyrimidine compounds as neurokinin antagonists | PREDIX PHARMACEUTICALS HOLDINGS, INC. | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249114-A1 | ARYLOXYPROPANOLAMINES, METHODS OF PREPARATION THEROF AND USE OF ARYLOXYPROPANOLAMINES AS MEDICAMENTS | ADRB3, ADRB1, ADRB2 | ADRB2 3/4885ADRB1 2/4885ADRB3 1/4885 |
| US-20140371203-A1 | Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors | KCNA3, KCNJ1, KCNJ11 | ADRB2 374/4885ADRB1 248/4885ADRB3 130/4885 |
| US-20160152634-A1 | THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS | KCNA3, KCNJ1, KCNJ11 | ADRB2 379/4885ADRB1 250/4885ADRB3 131/4885 |
| US-20040138238-A1 | Substituted aminopyrimidine compounds as neurokinin antagonists | TACR1, GRPR, BDKRB1 | ADRB2 192/4885ADRB1 136/4885ADRB3 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.